or advanced systemic therapy for prostate cancer. Data analysis included 182 patients who had a median pre-scan PSA level of 2.6 ng/mL Overall, 84% of the patients had positive PSMA-PET/CT results ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...

is emerging as a prominent leader in adopting advanced prostate cancer treatments and diagnostics, including ...

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

PSMA-PET imaging uses tiny amounts of radioactive "tracers," called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...

PSMA-PET leverages ‘radiotracers’ that bind to prostate cancer cells, making them visible on PET scans and providing functional imaging that reveals the biological activity of cancer.

Managing advanced prostate cancer is increasingly complex ... high tumor mutational burden for pembrolizumab, and PSMA-PET scans to guide 177 Lu PSMA therapy.” “Gaps remain in deciding ...

is emerging as a prominent leader in adopting advanced prostate cancer treatments and diagnostics, including Prostate-Specific Membrane Antigen (PSMA) PET scans and Stereotactic Body Radiotherapy ...

PSMA-PET imaging uses tiny amounts of radioactive "tracers," called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...